What baffles me is that anyone is baffled by Paxlovid getting an EUA before Revive. When are investors on any one of these boards going to actually look at the facts. The amount of folks that have invested in RVV that really have no clue on the world of biotech investing is crazy. Clinical trials are extremely expensive, that is why pre-revenue companies spend their entire lives trying to raise money, diluting their investors in hopes to stay afloat until they get a breakthrough and sell off to BP. Pfizer has a market cap of over 270 billion, Revive at their top was sitting around 170 million USD. Pfizer rolled through their trial with about 2200 patients in a few months because of near limitless cash. Revive has been sitting on 713 for over a year. That is not the FDA’s fault or Pfizer’s that’s reality. I am a Revive Bull and have been invested for well over two years but I am also experienced in the biotech space and understand the game. I 100% believe this drug works and once the results are finally unblinded it will be bought out, for how much all depends on how well it does work. There is still nothing approved for mild/moderate which is by far the biggest market(don’t forget Pfizer’s Paxlovid actually failed at the mild/moderate group and they stopped their trial early). The reason why Revive is where it is with it’s SP is because it has very little exposure as a biotech from Canada that trades on the OTC in the US. There are very few institutional investors currently which means Revive is held by a large percentage of broke retail investors that don’t understand the process. The FDA has nothing to do with Revive’s struggles, on the contrary the FDA were the ones that fast tracked them to a phase 3, the FDA allowed them to do something that they nearly never do. They allowed Revive to partially unblind their trial to help decide on an end point; they certainly didn’t have to do that. The FDA granted Revive orphan drug status to Bucillamine for liver transplants. Not to mention they just approved the type C meeting which historically is bullish for any company to get their product moved along. I personally have zero love for ANY government organization, in nearly every instance government organizations break way more than they fix. In Revive’s case they need to take a hard look in the mirror to find out what ails them! Looks like the first 3 million of their funding will close sometime this week and the next 2 million is a week or so away according to the underwriters. That coupled with the upcoming type C meeting while the world is starting to see another major spike in infections puts Revive in the drivers seat to finally finish this trial in a way that all investors will walk away smiling! GLTA!
